Back to Search
Start Over
The Emerging Role of Induced Pluripotent Stem Cells as Adoptive Cellular Immunotherapeutics.
- Source :
-
Biology [Biology (Basel)] 2023 Nov 11; Vol. 12 (11). Date of Electronic Publication: 2023 Nov 11. - Publication Year :
- 2023
-
Abstract
- Adoptive cell therapy (ACT) has transformed the treatment landscape for cancer and infectious disease through the investigational use of chimeric antigen receptor T-cells (CAR-Ts), tumour-infiltrating lymphocytes (TILs) and viral-specific T-cells (VSTs). Whilst these represent breakthrough treatments, there are subsets of patients who fail to respond to autologous ACT products. This is frequently due to impaired patient T-cell function or "fitness" as a consequence of prior treatments and age, and can be exacerbated by complex manufacturing protocols. Further, the manufacture of autologous, patient-specific products is time-consuming, expensive and non-standardised. Induced pluripotent stem cells (iPSCs) as an allogeneic alternative to patient-specific products can potentially overcome the issues outlined above. iPSC technology provides an unlimited source of rejuvenated iPSC-derived T-cells (T-iPSCs) or natural killer (NK) cells (NK-iPSCs), and in the context of the growing field of allogeneic ACT, iPSCs have enormous potential as a platform for generating off-the-shelf, standardised, "fit" therapeutics for patients. In this review, we evaluate current and future applications of iPSC technology in the CAR-T/NK, TIL and VST space. We discuss current and next-generation iPSC manufacturing protocols, and report on current iPSC-based adoptive therapy clinical trials to elucidate the potential of this technology as the future of ACT.
Details
- Language :
- English
- ISSN :
- 2079-7737
- Volume :
- 12
- Issue :
- 11
- Database :
- MEDLINE
- Journal :
- Biology
- Publication Type :
- Academic Journal
- Accession number :
- 37998018
- Full Text :
- https://doi.org/10.3390/biology12111419